secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001140361-22-040919
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant prices $150M primary/secondary offering at $5.00 per share
------------------------------------------------------------------

- Company sold 20M shares for ~$100M gross; selling shareholders sold 10M for ~$50M; $5.00/share.
- Underwriter granted 30-day option to purchase up to $22.5M additional common shares.
- Roivant expects cash position to fund operations into H2 2025; proceeds not received from selling shareholders.
- Offering closed on Nov 10, 2022; sole bookrunner Cantor Fitzgerald.
- Registration statement effective Oct 3, 2022; prospectus supplement filed Nov 8.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036122040919/0001140361-22-040919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036122040919/ny20005775x4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-040919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer